Weird Science LLC - 16 Feb 2018 Form 4 Insider Report for Enochian Biosciences Inc (RENB)

Role
10%+ Owner
Signature
/s/ William Anderson Wittekind, as Manager
Issuer symbol
RENB
Transactions as of
16 Feb 2018
Net transactions value
$0
Form type
4
Filing time
06 Feb 2023, 18:24:58 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RENB Common Stock Other +17,545,283 17,545,283 16 Feb 2018 Direct F1
transaction RENB Common Stock Other +1,268,880 +7.2% 18,814,163 31 Dec 2018 Direct F2
transaction RENB Common Stock Other +3,631,234 +19% 22,445,397 30 Jul 2019 Direct F2
transaction RENB Common Stock Other -17,545,283 -78% 4,900,114 29 May 2020 Direct F3
transaction RENB Common Stock Other +61,249 +1.2% 4,961,363 14 Dec 2020 Direct F2
transaction RENB Common Stock Other +97,032 +2% 5,058,395 11 Apr 2022 Direct F2
transaction RENB Common Stock Other -4,961,363 -98% 97,032 15 Apr 2022 Direct F3
transaction RENB Common Stock Other +1,216,467 +1254% 1,313,499 13 Oct 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Weird Science LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The Reporting Person received these shares as merger consideration in exchange for the Reporting Person's common stock of Enochian BioPharma, Inc., which the Issuer acquired by merger on February 16, 2018. In addition to such shares, the Agreement and Plan of Merger governing the merger (the "Merger Agreement") provides that upon the exercise or conversion of options and warrants to purchase shares of the Issuer's common stock that were outstanding as of the closing of the merger, the Issuer will issue a like number of shares of Common Stock (referred to as "Earn-Out Stock") to the former stockholders of Enochian BioPharma, Inc., including the Reporting Person, on a pro rata basis. The Reporting Person's right to receive additional shares of the Issuer's common stock as Earn-Out Stock became fixed and irrevocable on February 16, 2018, the closing date of the merger.
F2 Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement.
F3 Pro rata distribution to the members of the Reporting Person.